Skip to main content
SpringerLink
Log in

Einfluss von Tibolon auf das Brustdrüsengewebe

Effect of tibolone on mammary gland tissue

  • Published:
Gynäkologische Endokrinologie Aims and scope

Zusammenfassung

Die Hormonersatztherapie (HRT) ist zur Behandlung klimakterischer Symptome etabliert. Es konnte allerdings gezeigt werden, dass die HRT zu einem Mammakarzinomrisiko führt. Deshalb sind Substanzen von Interesse, die eine Behandlung klimakterischer Symptome zulassen, ohne mit einem erhöhten Mammakarzinomrisiko behaftet zu sein. Hier spielen insbesondere die selektiven Östrogenrezeptormodulatoren (SERMs) sowie die gewebeselektiven Regulatoren der Östrogenaktivität (STEARs) eine Rolle. Die Wirkungsweise von Tibolon als dem wichtigsten Vertreter der STEARs wird dargestellt. Im Vergleich zum Placebo bzw. zur herkömmlichen HRT führt Tibolon zu einer signifikanten Reduktion bzw. zu einer gleichwertigen Verminderung vegetativer Beschwerden. Tibolon zeigt einen günstigen Einfluss auf die Vita sexualis. Im Gegensatz zur HRT zeigt es keine Stimulation der Proliferationsrate des Brustdrüsengewebes. Durch Stimulation der Östrogenrezeptorexpression im Knochen und eine Verminderung der Knochenresorption bewirkt es eine Zunahme der Knochendichte. Aufgrund fehlender Stimulation des Endometriums kann Tibolon auch ohne Gestagenzusatz bei Frauen mit intaktem Uterus eingesetzt werden.

Abstract

Hormone replacement therapy (HRT) has been shown to significantly reduce postmenopausal symptoms. However, it has been shown that women under HRT are at increased risk for the development of breast cancer. Thus, drugs which effectively treat postmenopausal symptoms without affecting breast tissue are of interest. Two classes of drugs have been investigated extensively: selective estrogen receptor modulators (SERMs) and selective tissue estrogenic activity regulators (STEARs). Tibolone is the most renowned member of the STEAR family and its effects on climacteric symptoms are discussed. It has been shown that tibolone effectively reduces climacteric symptoms without stimulating proliferation of breast or endometrial tissue. Due to its estrogenic effects on the bone tibolone increases bone density. Because it does not stimulate the endometrium, tibolone can be administered, also without added gestagens, to women with an intact uterus.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3

Literatur

  1. Anderson GL, Limacher M, Assaf AR et al. (2004) Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women’s Health Initiative randomized controlled trial. JAMA 291:1701–1712

    CAS  PubMed  Google Scholar 

  2. Banks E, Beral V, Reeves G et al. (2004) Fracture incidence in relation to the pattern of use of hormone therapy in postmenopausal women. JAMA 291:2212–2220

    Article  CAS  PubMed  Google Scholar 

  3. Baracat EC, Barbosa IC, Giordano MG et al. (2002) A randomized, open-label study of conjugated equine estrogens plus medroxyprogesterone acetate versus tibolone: effects on symptom control, bleeding pattern, lipid profile and tolerability. Climacteric 5:60–69

    CAS  PubMed  Google Scholar 

  4. Beckmann, MW, Braendle W, Brucker C et al. (2003) Konsensusempfehlungen zur Hormontherapie (HAT) im Klimakterium und in der Postmenopause. Geburtsh Frauenheilk 63:209–212

    Article  Google Scholar 

  5. Bedenek-Jaszmann LJ (1987) Long-term placebo-controlled efficacy and safety study of ORG OD 14 in climacteric women. Maturitas Suppl 1:25–33

    Google Scholar 

  6. Beral V (2003) Million Women Study Collaborators. Breast cancer and hormone-replacement therapy in the Million Women Study. Lancet 362:419–427

    Article  PubMed  Google Scholar 

  7. Beral V, Banks E, Reees G (2002) Evidence from randomised trials on the long-term effects of hormone replacement therpy. Lancet 360:429–444

    Google Scholar 

  8. Berning B, Kuijk CV, Kuiper JW et al. (1996) Effects of two doses of tibolone on trabecular and cortical bone loss in early postmenopausal women: a two-year randomized, placebo-controlled study. Bone 19:395–399

    Article  CAS  PubMed  Google Scholar 

  9. Berning B, van Kuijk C, Bennink HJ et al. (2000) Absent correlation between vaginal bleeding and oestradiol levels or endometrial morphology during tibolone use in early postmenopausal women. Maturitas 35:81–88

    Article  CAS  PubMed  Google Scholar 

  10. Birkhäuser M, de Geytr Ch, Keller, PJ, Luzuy F (2003) Empfehlungen der Schweizerischen Menopausengesellschaft: Stellungnahme zur postmenopausalen Hormontherapie nach WHI und HERS. J Menopause 1:7–11

    Google Scholar 

  11. Bjarnason NH, Bjarnason K, Haarbo J et al. (1996) Tibolone: prevention of bone loss in late postmenopausal women. J Clin Endocrinol Metab 81:2419–2422

    Article  CAS  PubMed  Google Scholar 

  12. Bjarnason NH, Bjarnason K, Hassager C, Christiansen C (1997) The response in spinal bone mass to tibolone treatment is related to bone turnover in elderly women. Bone 20:151–155

    Article  CAS  PubMed  Google Scholar 

  13. Brown JS, Vittinghoff E, Kanaya AM et al. (2001) Heart and Estrogen/Progestin Replacement Stuy Research Group. Urinary tract infections in postmenopausal women: effect of hormone therapy and risk factors. Obstet Gynecol 98:1045–1052

    Article  CAS  PubMed  Google Scholar 

  14. Castelo-Branco C, Vicente J, Figueras F et al. (2000) Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. Maturitas 34:161–168

    Article  CAS  PubMed  Google Scholar 

  15. Cauley JA, Norton L, Lippman ME et al. (2001) Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation. Breast Cancer Res Treat 65:125–134

    Article  CAS  PubMed  Google Scholar 

  16. Chetrite G, Kloosterboer HJ, Pasqualii JR (1997) Effect of tibolone (Org OD14) and its metabolites on estrone sulphatase activity in MCF-7 and T-47D mammary cancer cells. Anticancer Res 17:135–140

    CAS  PubMed  Google Scholar 

  17. Cittadini J, Ben J, Badano AR et al. (1982) Use of a new steroid (Org OD 14) in the climacteric syndrome. Reprod 6:69–79

    CAS  Google Scholar 

  18. Cline JM, Register TC, Clarkson TB (2002) Effects of tibolone and hormone replacement therapy on the breast of cynomolgus monkeys. Menopause 9:422–429

    PubMed  Google Scholar 

  19. Collaborative Group on Hormonal Factors in Breast Cancer rest cancer and hormone replacment therapy (1997) Collaborative reanalysis of data from 51 epidemiological studies of 52705 Women with breast cancer and 108411 without breast cancer. Lancet 350:1047–1059

    Article  PubMed  Google Scholar 

  20. Conner P, Christow A, Kersemaekers W et al. (2004) A comparative study of breast cell proliferation during hormone replacement therapy: effects of tibolone and continous combined estrogen-progestogen treatment. Climacteric 7:50–58

    CAS  PubMed  Google Scholar 

  21. Crona N, Samsioe G, Lindberg UB, Silfverstolpe G (1988) Treatment of climacteric complaints with Org OD 14: a comparative study with oestradiol valerate and placebo. Maturitas 9:303–308

    CAS  PubMed  Google Scholar 

  22. Davis SR (2002) The effects of tibolone on mood and libido. Menopause 9:162–170

    Article  PubMed  Google Scholar 

  23. De Gooyer ME, Overklift Vaupel Kleyn GT, Smits KC et al. (2001) Tibolone a compound with tissue-specific inhibitory effects on sulfatase, Mol Cell End 183:55–62

  24. De Gooyer ME, Deckers GH, Schoonen WWGEJ et al. (2002) Receptor profiling and endocrine interactions of tibolone. Steroids 68:21–30

    Google Scholar 

  25. Delmas PD, Bjarnason NH, Mitlak BH et al. (1997) Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women. N Engl J Med 337:1641–1647

    Article  CAS  PubMed  Google Scholar 

  26. Diane S et al.: Pharmaceutical content and regimen of hormone replacement therapy and risk of breast cancer. Pharmacoepidemiol Drug Safety 11 [Suppl 1]:296 (Abstract)

  27. Doren M, Rubig A, Coelingh Bennink HJ, Holzgreve W (2001) Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and norethindrone acetate replacement therapy. Fertil Steril 75:554–559

    Article  CAS  PubMed  Google Scholar 

  28. Egarter C, Topcuoglu AM, Vogl S, Sator M (2002) Hormone replacement therapy with tibolone: effects on sexual functioning in postmenopausal women. Acta Obstet Gynecol Scand 81:649–653

    Article  PubMed  Google Scholar 

  29. Ettinger B, Black DM, Mitlak BH et al. (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple outcomes of raloxifene evaluation (MORE) investigators. JAMA 282:637–645

    Article  CAS  PubMed  Google Scholar 

  30. Gallagher JC, Baylink DJ, Freeman R, McClung M (2001) Prevention of bone loss with tibolone in postmenopausal women: results of two randomized, double-blind, placebo-controlled, dose-finding studies. J Clin Endocrinol Metab 86:4717–4726

    Article  CAS  PubMed  Google Scholar 

  31. Genazzani AR, Petraglia F, Facchinetti F et al. (1987) Effects of Org OD 14 on pituitary and peripheral beta-endorphin in castrated rats and post-menopausal women. Maturitas Suppl 1:35–48

    Google Scholar 

  32. Geusens P, Dequeker J, Gielen J, Schot LP (1991) Non-linear increase in vertebral density induced by a synthetic steroid (Org OD 14) in women with established osteoporosis. Maturitas 13:155–62

    CAS  PubMed  Google Scholar 

  33. Gompel A, Chaouat M, Jacob D et al. (2002): Fertil Steril 78:351–359

    Article  PubMed  Google Scholar 

  34. Gotzsche PC, Olsen O (2000) Is screening for breast cancer with mammography justifiable? Lancet 355:129–134

    Article  CAS  PubMed  Google Scholar 

  35. Grady D, Brown JS, Vittinghoff E et al. (2001) Postmenopausal hormones and incontinence: the HEART and Estrogen/Progestin Replacement Study: Obstet Gynecol 97:116–120

    Google Scholar 

  36. Hammar M, Christau S, Nathorst-Boos J et al. (1998) A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. Br J Obstet Gynaecol 105:904–911

    CAS  PubMed  Google Scholar 

  37. Early Breast Cancer Trialist Collaborative Group (1998) Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351:1451–1464

    Article  PubMed  Google Scholar 

  38. Helmond FA, Kloosterboer HJ (2002) Safety and tolerability profile of Livial. In: Genazzani AR (ed) Hormone replacement therapy and cancer. The Parthenon Publishing Group, London, pp 252–256

  39. Huber J, Palacios S, Berglund L et al. (2002) Effects of tibolone and continuous combined hormone replacement therapy on bleeding rates, quality of life and tolerability in postmenopausal women. BJOG 109:886–893

    CAS  PubMed  Google Scholar 

  40. Hulley S, Grady D, Bush T et al. (1998) For the heart and Estrogen/progestin replacement Study (HERS) Research Group. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. JAMA 280:605–613

    Article  CAS  PubMed  Google Scholar 

  41. Ke HZ, Qi H, Crawford DT et al. (2000) Lasofoxifene (CP-336, 156) a selective estrogen receptor modulator, prevents bone loss induced by aging and orchidectomy in the adult rat. Endocrinlogy 141:1338–1344

    Google Scholar 

  42. Kicovic PM, Cortes-Prieto J, Luisi M et al. (1982) Placebo-controlled cross-over study of effects of Org OD 14 in menopausal women. Reprod 6:81–91

    CAS  Google Scholar 

  43. Kloosterboer JH (2001) Tibolone: a steroid with a tissue-specific mode of action. J Steroid Biochem Mol Biol 76:231–238

    Article  CAS  PubMed  Google Scholar 

  44. Kloosterboer HJ (2004) Tissue-selectivity: the mechanism of action of tibolone. Maturitas 49 (in press)

  45. Kloosterboer HJ, Ederveen AGH (2002) Pros and cons of existing treatment modalities in osteoporosis: a comparison between tibolone, SERMs and estrogen (+/s progestogen) treatments. J Steroid Biochem Mol Biol 83:157–165

    Article  CAS  PubMed  Google Scholar 

  46. Kökcü A, Cetinkaya MB, Yanik F et al. (2000) The comparison of effects of tibolone and conjugated estrogen-medroxyprogesterone acetate therapy on sexual performance in postmenopausal women. Maturitas 36:75–80

    Article  PubMed  Google Scholar 

  47. Laan E, van Lunsen RH, Everaerd W (2001) The effects of tibolone on vaginal blood flow, sexual desire and arousability in postmenopausal women. Climacteric 4:28–41

    CAS  PubMed  Google Scholar 

  48. Lindsay R, Hart DM, Kraszewski A (1980) Prospective double-blind trial of synthetic steroid (Org OD 14) for preventing postmenopausal osteoporosis. Br Med J 280:1207–1209

    CAS  PubMed  Google Scholar 

  49. Love RR, Mazess RB, Barden HS et al. (1992) Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer. N Engl J Med 326:852–856

    CAS  PubMed  Google Scholar 

  50. Lundstrom E, Christow A, Kersemaekers W et al. (2002) Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. Am J Obstet Gynecol 186:717–722

    Article  CAS  PubMed  Google Scholar 

  51. McLennan A, Lester S, Moore V et al. (2001) Oral estrogen replacement therapy versus placebo for hot flushes: a systematic review. Climacteric 4:58–74

    PubMed  Google Scholar 

  52. McLennan A, Lester S, Moore V et al. (2001) Oral replacement therapy verus placebo for hot flushes. (Cochrane Review). Cochrane Database Syst Rev CD 002978

  53. Medical Marketing Research International by Organon: Report 2000

  54. Miller CP, Harris HA, Komm BS (2002) Bazedoxifene acetate: selective estrogen receptor modulator, treatment and prevention of osteoporosis. Drugs Future 27:117–121

    CAS  Google Scholar 

  55. Nathorst-Boos J, Hammar M (1997) Effect on sexual life—a comparison between tibolone and a continuous estradiol-norethisterone acetate regimen. Maturitas 26:15–20

    Article  CAS  PubMed  Google Scholar 

  56. Netelenbos JC, Siregar-Emck MT, Schot LP et al. (1991) Short-term effects of Org OD 14 and 17 beta-oestradiol on bone and lipid metabolism in early post-menopausal women. Maturitas 13:137–149

    CAS  PubMed  Google Scholar 

  57. Nevinny-Stickel J (1983) Double-blind cross-over study with Org OD 14 and placebo in postmenopausal patients. Arch Gynecol 234:27–31

    CAS  PubMed  Google Scholar 

  58. Palacios S, Menendez C, Jurado AR et al. (1995) Changes in sex behaviour after menopause: effects of tibolone. Maturitas 22:155–161

    Article  CAS  PubMed  Google Scholar 

  59. Pasqualini JR (1997) Role, control and expression of estrone sulfatase and 17 beta-hydroxysteroid dehydrogenase activities in human breast cancer. Zentralbl Gynaekol 119 [Suppl 2]:48–53

    Google Scholar 

  60. Reed MJ (2004) Role of enzymes and tissue-specific actions of steroids. Maturitas 49 (in press)

  61. Rymer J, Robinson J, Fogelman I (2002) Ten years of treatment with tibolone 2.5 mg daily: effects on bone loss in postmenopausal women. Climacteric 5:390–398

    CAS  PubMed  Google Scholar 

  62. Siseles NO, Halperin H, Benencia HJ et al. (1995) A comparative study of two hormone replacement therapy regimens on safety and efficacy variables. Maturitas 21:201–210

    Article  CAS  PubMed  Google Scholar 

  63. Smith CL, O’Malley BW (2004) Coregulator function: a key to understanding tissue specificity of selective receptor modulators. Endocrine Rev 25:45–71

    Article  CAS  Google Scholar 

  64. Stahlberg C, Pedersen AT, Lynge E et al. (2004) Increased risk of breast cancer following different regimens of hormone replacement therapy frequently used in Europe. Int J Cancer 109:721–727

    Article  CAS  PubMed  Google Scholar 

  65. Suh N, Glasebrook AL, Palkowitz A et al. (2001) Arzoxifene, a new selective estrogen receptor modulator for chemoprevention of experimental beast cancer. Cancer Res 61:8412–8415

    CAS  PubMed  Google Scholar 

  66. Tang B, Markiewicz L, Kloosterboer HJ, Gurpide E (1993) Human endometrial 3β-hydroxysteroid dehydrogenase/isomerase can locally reduce intrinsic estrogenic/progestagenic activity ratios of a steroidal drug (Org OD14). J Steroid Biochem Mol Biol 45:345–351

    Article  CAS  PubMed  Google Scholar 

  67. Torgerson DJ, Bell-Syer SE (2001) Hormone replacement therapy and prevention of nonvertebral fractures a meta-analysis of randomized trials. JAMA 285:2891–2897

    Article  CAS  PubMed  Google Scholar 

  68. Valdivia I, Campodonico I, Tapia A et al.: Effects of tibolone and continuous combined hormone therapy on mammographic breast density and breast histochemical markers in postmenopausal women. Fertil Steril 81:617–623

  69. Velthuis EJM, Hendricks PT, Boerstoel-Streefland M (2004) Clinical background of women prescribed tibolone or menopausal estrogen + progestogen therapie (EPT): a UK Mediplus study. Climacteric (in press)

  70. Winkler UH, Altkemper R, Kwee B et al. (2000) Effects of tibolone and continuous combined hormone replacement therapy on parameters in the clotting cascade: a multicenter, double-blind, randomized study. Fertil Steril 74:10–19

    Article  CAS  PubMed  Google Scholar 

  71. Writing Group for the Women’s Health Iitiative Investigators (2002) Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women’s Health Initiative Randomized Controlled Trial. JAMA 288:321–333

    CAS  PubMed  Google Scholar 

Download references

Interessenkonflikt:

Keine Angaben

Author information

Authors and Affiliations

  1. Universitäts-Frauenklinik Freiburg

    C. Keck & C. Tempfer

  2. Universitäts-Frauenklinik, Hugstetter Straße 55, 79106 , Freiburg

    C. Keck

Authors
  1. C. Keck
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Tempfer
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C. Keck.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Keck, C., Tempfer, C. Einfluss von Tibolon auf das Brustdrüsengewebe. Gynäkologische Endokrinologie 2, 153–158 (2004). https://doi.org/10.1007/s10304-004-0068-3

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10304-004-0068-3

Schlüsselwörter

Keywords

Search

Navigation